Table 3: Current HAART regimens of the study participants.
| Regimens |
Case n (%) |
Control n (%) |
| AZT + 3TC + NVP |
26(21.66) |
25(20.84) |
| AZT + 3TC + EFV |
11(9.17) |
21 (17.50) |
| TDF + 3TC + EFV |
41(34.16) |
33(36.26) |
| TDF + 3TC + NVP |
14(11.676) |
11(27.50) |
| TDF + 3TC + ATV/r |
5 (4.17) |
10(8.34) |
| ABC + DDI + LPV/r |
5 (4.17) |
6(5) |
| ABC + DDI + EFV |
5 (4.17) |
6(5) |
| AZT + 3TC + ATV/r |
8 (6.67) |
4 (3.33) |
| ABC + 3TC + ATV/r |
5(4.17) |
4(3.33) |
3TC: Lamivudine; NVP: Nevirapine; EFV: Efavirenz, AZT: Zidovudine: TDF: Tenofovir; ABC: Abacavir; DDI: Didanosine; ATV/r: Atazanavir-ritonavir; LPV/r: Lopinavir-ritonavir